Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea

Follicular Lymphoma Clinical Trial

— FLPOD24  

Official title:

Clinical Outcomes of Early-progressed Follicular Lymphoma in Korea : A Multicenter, Retrospective Analysis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04048395
• Other study ID #: 2019-04-027
• Status: Recruiting
• Start date: July 8, 2019
• Est. completion date: April 30, 2020

Study information

• Verified date: August 2019
• Source: Samsung Medical Center
• Contact: Wonseog Kim, Professor
• Phone: +82-02-3410-6548
• Email: wonseog.kim[@]samsung.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This retrospective study was proposed by the investigators to analyze treatment status and outcome in patients with early relapsed follicular lymphoma. In patients with follicular lymphoma who experienced disease progression within 24 months after initiation of treatment, the second-line therapy, stem cell transplantation, tumor response, progression free survival, and overall survival will be analyzed.

Description:

Follicular lymphoma is the second most common non-Hodgkin's lymphoma in Western countries, but it is relatively less frequent in Asia. As a result, the prognosis and treatment status in Korean patients with follicular lymphoma have been rarely studied.

With the recent addition of monoclonal antibodies targeting CD20 into existing cytotoxic chemotherapy, the overall life expectancy of patients with follicular lymphoma has improved a lot. However, nearly 20% of these patients experience early worsening of disease within the first 24 months of treatment, followed by poor prognosis. Since patients with early relapse within 24 months usually experience worsening of disease during treatment with rituximab combined with chemotherapy or during rituximab maintenance therapy, optimal treatment for such patients is unknown, but remission induction therapy followed by stem cell transplantation, bendamustine combined with obinutuzumab, PI3K inhibitors, and lenalidomide are possible options. However, most of these drugs are limited for use in Korea, and there is little information with regard to treatment guidelines for patients with early relapsed follicular lymphoma or their treatment outcome in Korea.

This retrospective study was proposed by the investigators to analyze treatment status and outcome in patients with early relapsed follicular lymphoma. This study will provide basic data for follicular lymphoma study in Korea and for future clinical trial design.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: April 30, 2020
• Est. primary completion date: April 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

1. Patients histologically diagnosed with follicular lymphoma (ICD-10 C82.0 to C82.9)

2. Radiologically confirmed disease progression within 24 months from the start date of an induction chemotherapy

3. All of the following should be available for retrospective analysis.

• Pathologic findings report

• Medical records containing age, sex, date of diagnosis, clinical symptoms, laboratory findings, treatment methods, progression, survival, death, etc.

Exclusion Criteria:

1. Known histologic transformation to aggressive lymphoma

2. Follicular lymphoma grade 3B

3. Patients whose pathologic findings report and appropriate medical records are not available

Related Conditions & MeSH terms

• Follicular Lymphoma
• Lymphoma
• Lymphoma, Follicular

Locations

Country	Name	City	State
Korea, Republic of	81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	Overall survival is defined as the time from the diagnosis to death or last follow-up.	from the date of the IRB approval until 12 month
Secondary	Progression free survival	Progression free survival is defined as the time from diagnosis to relapse, disease progression, or last follow-up	from the date of the IRB approval until 12 month